Start here if you're new
what it is
Merck sells prescription drugs, vaccines, biologic therapies, and animal-health products, with its drug business producing 89% of 2025 sales.
how it gets paid
Last year Merck & made $65.0B in revenue. Oncology was the main engine at $29.5B, or 45% of sales.
why it's growing
Revenue grew 1.3% last year. Subscribers may recall that merck paused shipments of its hpv vaccine to china earlier this year due to persistent weakness in market demand.
what just happened
The latest print was a small beat, with EPS at $2.09 versus $2.07 expected, according to consensus data.
At a glance
A balance sheet — strong enough to weather a downturn
40/100 earnings predictability — expect surprises
11.1x trailing p/e — the market's not buying it — or you found a deal
3.4% dividend yield — cash in your pocket every quarter
30.0% return on capital — every dollar works hard here
xvary composite: 78/100 — average
What they do
Merck sells prescription drugs, vaccines, biologic therapies, and animal-health products, with its drug business producing 89% of 2025 sales.
Doctors do not swap serious therapies casually. That habit shows up in the numbers: pharmaceuticals were 89% of Merck's 2025 sales, or about $58.1 billion. Switching costs (changing treatments) → patients and doctors stick with what works → so what: your revenue stream gets more durable than most businesses.
How they make money
$65.0B
annual revenue · their business grew +1.3% last year
Oncology
$29.5B
+17.0%
Vaccines
$10.8B
3.0%
Hospital & specialty care
$17.9B
+4.0%
Animal Health
$6.35B
+4.0%
Other
$0.52B
flat
The products that matter
commercial drug portfolio
Prescription medicines
$65.0B revenue base
this is the part of the story investors instinctively anchor on. the snapshot gives you the full $65.0B company revenue but not the product split underneath it, which tells you how much the market is focused on the lead franchises.
core engine
vaccines and biologic therapies
Vaccines and biologics
part of a $65.0B portfolio
Merck explicitly sells vaccines and biologic therapies, but this page does not break them out separately. you are underwriting pieces of a $65.0B business without a clean segment bridge.
mix matters
future growth optionality
Pipeline and launches
11.1x earnings
the rerating case needs more than a sturdy base business. at 11.1x earnings, the market is saying future growth deserves proof, not applause.
next act
Key numbers
11.1x
trailing p/e
P/E (price-to-earnings ratio) → what you pay for each dollar of profit → so what: Merck is priced like a slower, riskier business than its 39.0% margin suggests.
39.0%
operating margin
Operating margin → profit left after running the business → so what: Merck keeps 39 cents from each sales dollar before interest and taxes.
30.0%
return on capital
Return on capital → profit earned on the money invested in the business → so what: every $1 Merck puts to work produces about $0.30 in operating profit.
3.4%
dividend yield
Dividend yield → cash paid to you each year as a share of the stock price → so what: you get paid while waiting for the pipeline to prove itself.
Financial health
A
strength
- balance sheet grade A — very strong financial position
- risk rank 2 — safer than 80% of stocks
- price stability 85 / 100
- long-term debt $40.0B (14% of capital)
- net profit margin 35.8% — keeps 36 cents of every dollar in revenue
- return on equity 46% — $0.46 profit for every $1 investors have put in
A with balance sheet grade and risk rank standing out. your money faces less risk here than at most public companies.
Total return vs. market
You invested $10,000 in MRK 3 years ago → it's now worth $10,020.
The index would have given you $13,920.
source: institutional data · total return
What just happened
beat estimates
The latest print was a small beat, with EPS at $2.09 versus $2.07 expected, according to consensus data.
Value Line says third-quarter adjusted EPS jumped 64% vs. prior year to $2.58, helped by continued business momentum. There is a source mismatch on the latest quarter: consensus shows $2.09 EPS, while Value Line's 2025 quarterly table lists Q4 EPS at $2.07; both still point to full-year 2025 EPS of $9.00.
$15.6B
ttm revenue
$2.09
latest eps
39.0%
operating margin
the number that mattered
The number that mattered was $9.00 in full-year 2025 EPS, because it set up Value Line's $9.75 fiscal 2026 estimate and keeps the stock near 10x to 11x earnings.
-
merck performed well in the third quarter.
-
adjusted earnings soared 64% from a year ago, to $2.58 a share, bolstered by continued momentum in the company’s blockbuster keytruda franchise and strong contributions from newer drugs including winrevair and capvaxive.
-
these catalysts helped to mitigate lingering challenges with gardasil in asia.subscribers may recall that merck paused shipments of its hpv vaccine to china earlier this year due to persistent weakness in market demand.
-
softer dynamics in japan have also taken a toll on gardasil in 2025.
-
we raised our estimates.september-period earnings surpassed our call by $0.20 a share, with much of the upside coming from growth in prescription medicines and animal health products.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk here is prescription-medicine concentration — this snapshot gives you revenue, margin, and valuation, but not the product-level bridge that would show how diversified the growth really is.
med
lead-franchise concentration
The page keeps circling back to Prescription Medicines for a reason. When the main portfolio carries the narrative, weaker growth elsewhere matters more than the headline suggests.
If the lead portfolio slows, the stock can keep looking like an 11.1x earnings business even with strong margins.
med
revenue durability
Merck posted a 2% decline from a year earlier in early 2025. One soft period is survivable. A repeat would make the $69B fy2026 revenue target harder to trust.
That pressure shows up first in sentiment, then in the multiple, then in the rerating case.
med
earnings volatility
Earnings predictability is 40/100. In human-speak: the balance sheet is dependable, but the quarterly read can still get messy.
That raises the odds that guidance, mix, or one weak quarter matters more than a 3.4% yield suggests.
med
cheap can stay cheap
Stocks do not rerate because investors notice they are inexpensive. They rerate when the market starts trusting the next few years more than the last few quarters.
You can collect the dividend while you wait, but stagnant sentiment can still leave returns stuck near the last three-year result.
If revenue keeps wobbling while the lead portfolio does more of the work, Merck can remain an 11.1x earnings story instead of becoming a rerating story.
source: institutional data · regulatory filings · risk analysis
Pay attention to
earnings
next earnings update
The next report matters less for headline size than for whether management restores confidence after the early 2025 revenue dip.
trend
revenue path toward $69B
This is the cleanest operating checkpoint on the page. If revenue starts tracking toward the fy2026 estimate, the low multiple gets harder to justify.
risk
product concentration
This snapshot is thinner on franchise mix than you would want. Any update that clarifies which products are carrying growth deserves extra attention.
metric
40/100 predictability
That score is the quiet warning sign. If the business keeps surprising the market, the rerating case stays on a leash.
Analyst rankings
short-term outlook
top 20%
momentum score 2 — in human-speak, analysts still expect better-than-average price performance in the year ahead.
balance-sheet safety
safer than most
stability score 2 — safer than roughly 80% of stocks.
chart momentum
below average
technical score 4 — the tape is weaker than the balance sheet.
earnings predictability
40 / 100
quarterly results can surprise you more than an A-rated balance sheet would suggest.
source: institutional data
Institutional activity
institutions have been net selling for 3 consecutive quarters — 1,508 buyers vs. 1,523 sellers in 3q2025. total institutional holdings: 1.9B shares. net selling for 3 quarters.
source: institutional data
Price targets
3-5 year target range
$85
$178
$100
current price
$132
target midpoint · +32% from current · 3-5yr high: $175 (+75% · 17% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive